WO2012134251A2 - Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys - Google Patents

Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys Download PDF

Info

Publication number
WO2012134251A2
WO2012134251A2 PCT/KR2012/002467 KR2012002467W WO2012134251A2 WO 2012134251 A2 WO2012134251 A2 WO 2012134251A2 KR 2012002467 W KR2012002467 W KR 2012002467W WO 2012134251 A2 WO2012134251 A2 WO 2012134251A2
Authority
WO
WIPO (PCT)
Prior art keywords
pancreatic cancer
composition
extract
present
persimmon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/002467
Other languages
English (en)
Korean (ko)
Other versions
WO2012134251A3 (fr
Inventor
황성연
정경채
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOREA BIO MEDICAL SCIENCE INSTITUTE
Original Assignee
KOREA BIO MEDICAL SCIENCE INSTITUTE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOREA BIO MEDICAL SCIENCE INSTITUTE filed Critical KOREA BIO MEDICAL SCIENCE INSTITUTE
Publication of WO2012134251A2 publication Critical patent/WO2012134251A2/fr
Publication of WO2012134251A3 publication Critical patent/WO2012134251A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a novel use of persimmon extract. Specifically, the present invention relates to a therapeutic composition and a cosmetic composition containing as an active ingredient extracts persimmon extract showing excellent preventive or therapeutic efficacy against pancreatic cancer.
  • pancreas produces insulin, which helps the body convert glucose into energy, and enzymes that help the body digest food.
  • Pancreatic cancer is a malignant growth of the pancreas, mainly occurring in cells of the pancreatic duct. The disease is the ninth most common form of cancer, but it is the fourth and fifth most common cause of cancer deaths in men and women, respectively. Pancreatic cancer has a five-year survival rate of less than 3%, most of which is always fatal.
  • Pancreatic ductal adenocarcinoma (pancreatic ductal adenocarcinoma) in the pancreatic cancer which accounts for more than 90% of pancreatic cancer generally refers to pancreatic adenocarcinoma.
  • Pancreatic adenocarcinoma is also called pancreatic adenocarcinoma, pancreatic adenocarcinoma, or pancreatic adenocarcinoma.
  • pancreatic cancer arises from the accumulation of acquired mutations. Multiple genetic and epigenetic changes, including activation of protocogenes, inactivation of tumor suppressor genes, and malformations of maintenance genes, may result in the development, sustained growth, and metastasis of pancreatic cancer. Related to Accumulated mutations in such genes are known to occur within predictable time during the "PanINs" (Pancreatic Intraepithelial Neoplsia) phase (Hruban et al. (2000) Clin Cancer Res 6: 2969-2972; Kern (2002) Cancer Biol Therapy 1: 607-613; Li et al. (2004) Lancet 363: 1049-1057). K-ras mutations occur about half of PanIN-1.
  • PanIN-2 stage is represented by additional changes and increases in the rate of K-ras mutations, and the appearance of multiple p16 malformations, and p53 protein family expression, which may indicate the presence of p53 mutations, sometimes occurs in more advanced PanINs.
  • Loss of the tumor suppressor genes, TP53, DPC4 and BRCA2 appears to occur late in the development of pancreatic tumorigenesis, PanIN-3.
  • more than 85% of pancreatic adenocarcinomas have K-ras gene point mutations activated in pancreatic cancer development (Li et al. (2004) Lancet 363: 1049-1057; Xiong (2004) Cancer Chem Pharm 54: S69-77).
  • K-ras mutations induce constitutive activation of Ras-Raf-MEK-ERK, an intracellular signaling pathway that induces cell proliferation and confers transgene properties on cells containing point mutations.
  • Ras mutations are not associated with tumor stage or prognosis, and indicate that the K-ras oncogene may be involved in the onset of carcinogenesis but not in the likelihood or promotion of human pancreatic cancer.
  • One of the major downstream targets of the ras family is phosphoinositol 3 kinase (PI3K). Activation of PI3K is associated with pancreatic cancer resistance to apotosis induced by chemotherapy or molecular drug targeting agents.
  • Pancreatic adenocarcinoma is one of the most deadly human malignancies with more than 30,000 deaths annually in the United States alone. At diagnosis these cancers are found in a state where only 10% to 15% can be excised due to the presence of locally advanced disease or distant metastasis. Recently, the most common treatment strategy for advanced pancreatic cancer is gemcitabine, a 2'-deoxycytidine nucleoside analog for intravenous administration that can induce apoptosis of human pancreatic cancer cells and inhibit tumor growth and progression. It is a treatment by. However, despite the best medical or surgical treatment, the results of treatment of patients with pancreatic adenocarcinoma are terrible, and as a group, the median survival of patients with this disease is 21 months or less.
  • pancreatic cancer is a major health issue in developed countries and has a very poor prognosis (Faint et al. (2004) Datamonitor DMHC2045; Garcea et al. (2005) Pancreatology 5: 514-529; Kern et al. (2002). ) Cancer Biol Therapy 1: 607-613; Laheru and Jaffee (2005) Nature Rev Cancer 5: 59-467; Li et al. (2004) Lancet 363: 1049-1057). Despite excessive surgical and medical treatment, the mean life expectancy is about 15-18 months for patients with local disease and 3-6 months for patients with metastatic disease.
  • pancreatic cancer Nearly 100% of patients with pancreatic cancer experience metastasis and die due to their unrestricted growth, which weakens metabolism, and less than 5% of patients who have not undergone resection survive a total of 5 years. Do. In addition, there is a problem that the initial diagnosis is difficult due to the non-specific initial symptoms.
  • early detection of pancreatic cancer is still under development and not commercially available, and conventional cancer treatments have little effect on prognosis or disease outcome. Poor prognosis for pancreatic cancer is due to late manifestation, aggressive local invasion, early metastasis and insufficient response to chemotherapy.
  • pancreatic cancer The most common symptoms of pancreatic cancer include jaundice, abdominal pain and weight loss, and are not substantially special along with other emergence factors. Thus, diagnosing pancreatic cancer at an early stage of tumor growth is often difficult and requires a situation that includes considerable doubt and extensive diagnostic overhauls, often exploratory surgery. Endoscopic ultrasonography and computed tomography (CT) are the best noninvasive methods currently available for diagnosing pancreatic cancer. However, as well as differentiation of pancreatic cancer from lesioned pancreatitis, reliable detection of small tumors is difficult. Unfortunately, the majority of patients are currently diagnosed at a late stage where the tumor has already invaded the surrounding organs, extending outward and / or extensively metastasized (Gold et al., Crit. Rev. Oncology / Hematology, 39: 147-54 (2001). The disease is late detection is common, and early diagnosis of pancreatic cancer is rare in clinical settings.
  • a sense songhyang (Nardostachytis Rhizoma) is used as the root of a perennial plant of a sense songhyang (nardostachys Batalin chinensis) stomach pain, stomach cramps, thoracoabdominal coupon, neurogenic gastrointestinal disorders, vomiting, headache, or the like, respectively.
  • Nardostachys jatamansi (NJ) has been used extensively as a tonic, irritant and anticonvulsant in several Asian countries, as well as to treat epilepsy, pathological excitement, palpitations and spasms (Bagchi, A., et al. , Planta Med., 57, 9697 (1991)).
  • Perennial perennial persimmon roots include 1-aristol-2-one, nardostachone, 1,8,9,10-tetrad-hydroaristolan-2- components such as one) are contained.
  • the self-acting effect of the sensational sensation relieves pain caused by abdominal pain and chest abdominal pain, and is also applied to neuropathic pain and headache. Wash each affected area by adding water to it. It acts on the central nervous system and has a calming effect, such as heel chogeun ( ⁇ ⁇ ).
  • heart rate control is remarkable, and smooth muscle spasm of the bronchus, small intestine, large intestine, and uterus is released. Minor but also antibacterial.
  • the present inventors completed the present invention by confirming that the extract of the extract of Persimmon can effectively kill the pancreatic cancer cells during the herbal research on the extract.
  • the present invention provides a composition for the prevention and treatment of pancreatic cancer comprising an active ingredient extracted from persimmon ( Nardostachyos Rhizoma ) with an organic solvent.
  • the organic solvent is preferably ethanol.
  • the present invention provides a cosmetic composition for preventing pancreatic cancer, which contains a sensitized ethanol extract containing an cosmetically acceptable cosmetic auxiliary additive as an active ingredient.
  • the present invention provides a composition for the prevention and treatment of pancreatic cancer containing Nardostachyos Rhizoma ethanol extract as an active ingredient.
  • the composition of the present invention contains the extract of Persimmon as an active ingredient, and may further include a pharmaceutically acceptable carrier or diluent.
  • the ethanol extract is preferably extracted for 24 hours at 50 °C, wherein the ethanol extract is more preferably dried and concentrated at 45 °C reduced pressure conditions, the ethanol is Most preferred is 95%.
  • the pancreatic cancer is preferably kind cell cancer.
  • the persimmon extract of the present invention is possible at any site of persimmon, but is preferably extracted from the root.
  • the extraction solution may be obtained by extraction with water or an organic solvent, and examples of the organic solvent may include lower alcohols, acetone, chloroform, methylene chloride, ether, ethyl acetate, and hexane.
  • Lower alcohols include methanol, ethanol, propanol and butanol, with ethanol being most preferred.
  • ethanol 1 to 5 times, preferably 3 times, 95% ethanol is added to the dried persimmon fragrance or powder, and 10 to 100 hours, preferably 15 at a temperature of 20 to 100 ° C, preferably 40 to 60 ° C.
  • 10 to 100 hours preferably 15 at a temperature of 20 to 100 ° C, preferably 40 to 60 ° C.
  • To 40 hours, more preferably, for 24 hours after extraction can be filtered to prepare an ethanol extract of persimmon flavor.
  • the filtrate obtained by filtering the extract may be concentrated under reduced pressure.
  • the extraction process may be repeated two or more times as necessary, and the extract obtained after filtration may be lyophilized or dried under reduced pressure to obtain a powder form.
  • the "pharmaceutically acceptable carrier” is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.
  • composition for treating pancreatic cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient.
  • the carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
  • Formulation for pharmacological extracts of the present invention can be administered orally during clinical administration and can be used in the form of general pharmaceutical formulations, when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants And diluents such as surfactants or excipients.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc.
  • liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.
  • various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.
  • the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set (Uncaria) Uncus, Ponciri Fructus, Ginseng, Gingseng, Liriopis Tuber, Poly
  • composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • calcium or vitamin D 3 may be added to enhance the efficacy of the treatment.
  • Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as water for injection Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.
  • the formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination.
  • the invention also includes formulations of dosage units.
  • the formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage.
  • Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times.
  • the individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.
  • extract refers to an active ingredient isolated from natural products.
  • the extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.
  • the ethanol extract of S. fennel kills 82.8% of Panc-1 pancreatic cancer cells at 100 ⁇ g / ml and the EC 50 (half maximal effective concentration) was 50.5 ⁇ g / ml.
  • the above results demonstrate that the extract of Persimmon Fructus of the present invention has excellent killing activity of Panc-1 pancreatic cancer cells and further has pancreatic cancer treatment and prophylactic activity.
  • prevention means any action that inhibits or delays the development of pancreatic cancer by administration of the composition.
  • treatment means any action that improves or beneficially alters the symptoms of pancreatic cancer by administration of the composition.
  • Persimmon extract in the present invention can be used to extract using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol.
  • the extracted solution can be used directly or can be concentrated and / or dried.
  • methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized.
  • the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent.
  • the extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
  • Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.
  • Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration.
  • the drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.
  • the extract can perform an additional fractionation process.
  • the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • the term "pharmaceutically acceptable salts” means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases.
  • suitable acids include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid , Benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
  • Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.
  • the pharmaceutical composition for preventing and treating pancreatic cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition.
  • the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like.
  • the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as.
  • the composition may include a substance having a therapeutic activity against pancreatic cancer, used alone or previously used.
  • the term "patient” refers to humans and horses, sheep, pigs, goats, camels, who have diseases caused by pancreatic cancer and its direct and indirect causes, and whose symptoms may be improved by administering the composition of the present invention. Means antelope, dog and other animals.
  • a composition comprising the persimmon extract of the present invention, it is possible to effectively prevent and treat the above-mentioned pancreatic cancer.
  • the composition of the present invention can be administered in parallel with existing pancreatic cancer therapeutics.
  • the term "administration” means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered.
  • the composition may be administered by any device in which the active agent may migrate to the target cell.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses.
  • the method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration.
  • the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day.
  • Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.
  • the present invention provides a cosmetic composition for preventing pancreatic cancer, which contains a ethanol extract of Nardostachyos Rhizoma containing an cosmetically acceptable cosmetic supplement additive as an active ingredient.
  • the cosmetic composition of the present invention preferably contains 0.01 to 10% by weight, and more preferably 0.1 to 1% by weight, based on the total weight of the ethanol extract.
  • the cosmetic composition of the present invention is not particularly limited in the formulation, for example, it may have a flexible cosmetic water, nourishing cosmetics, massage cream, nutrition cream, pack, gel or skin adhesive type cosmetic formulation, and also lotion, It may be a transdermal dosage form such as an ointment, gel, cream, patch or spray.
  • the present invention was completed by preparing a cosmetic composition for preventing pancreatic cancer containing the extract of Persimmon as an active ingredient (see Preparation Example 2 ).
  • the extract of the present invention inhibits the growth of pancreatic cancer cells and induces apoptosis. Therefore, the composition for treating pancreatic cancer according to the present invention will be very effective for the treatment of pancreatic cancer patients.
  • Panc-1 cells which are human pancreatic cancer cells, wherein the X-axis is the concentration of the extract of the sensation, and the Y-axis is alive human pancreatic cancer The viability of the cells is shown.
  • Panc-1 cells which are human pancreatic cancer cells
  • the Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.
  • Panc-1 cells a pancreatic cancer cell line used in the present invention, were distributed from the Korean Cell Line Bank (KCLB) and used for experiments. Specifically, Panc-1 pancreatic cancer cells are DMEM (Dulbeco's Modified Eagle's) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Medium) was passaged in medium.
  • DMEM Dulbeco's Modified Eagle's
  • FBS fetal bovine serum, fetal bovine serum
  • HEPES 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid
  • Example 1 inhibits the growth of Panc-1 cells, which are pancreatic cancer cells. Specifically, 4.5 ⁇ 10 per well in a 96 well plate 3 Panc-1 pancreatic cancer cells were seeded and incubated for 24 hours, and the persimmon scent dissolved in dimethyl sulfoxide (DMSO) When the ethanol extract was treated at concentrations of 0 to 100 ⁇ g / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50 and 100 ⁇ g / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1).
  • DMSO dimethyl sulfoxide
  • Table 1 Sensation concentration Pancreatic cancer cell survival rate (average) Standard Deviation 0 ⁇ g / ml 1.000 0.000 3.125 ⁇ g / ml 0.917 0.080 6.25 ⁇ g / ml 0.862 0.058 12.5 ⁇ g / ml 0.837 0.065 25 ⁇ g / ml 0.773 0.059 50 ⁇ g / ml 0.593 0.058 100 ⁇ g / ml 0.172 0.008
  • the sweet scent has a pancreatic cancer treatment effect. That is, 8.3% at 3.125 ⁇ g / ml, 13.8% at 6.25 ⁇ g / ml, 16.3% at 12.5 ⁇ g / ml, 22.7% at 25 ⁇ g / ml, 40.7% at 50 ⁇ g / ml, and 82.8% at 100 ⁇ g / ml.
  • Pancreatic cancer cells were killed.
  • an EC 50 half maximal effective concentration
  • Table 1 above describes the relative cell numbers of pancreatic cancer cells after 48 hours according to the concentrations of each cheongsam, based on the number of survival rates of the pancreatic cancer cells of the control group which had not been treated with saccharin.
  • the extract of Persimmon Fragrance of the present invention has excellent Panc-1 cell killing activity and further demonstrates pancreatic cancer treatment and prophylactic activity.
  • the sensational fragrance used in the present invention was widely used as a medicinal herb, so it was determined that there was no problem in stability, but the oral administration and the intraperitoneal administration were performed by conducting toxicological tests.
  • Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally administered at a dose of 5 g / kg in suspension of the persimmon extract of Example 1 of the present invention in 0.5% methylcellulose solution, respectively. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed, and autopsy was performed to observe abdominal and thoracic organ abnormalities.
  • pancreatic cancer treatment effect of the extract persimmon yanghyang through the above embodiment was excellent to prepare a pancreatic cancer treatment containing the extract as an active ingredient as follows.
  • preparation of the following therapeutic agents can be used for the application of not only therapeutic agents but also cosmetic compositions.
  • the present inventors have confirmed that the extract persimmon extract is excellent pancreatic cancer therapeutic activity through the above Example to prepare a cosmetic composition containing it as an active ingredient as follows.
  • the nourishing cream was prepared by a conventional method according to the composition described below.
  • Glycerin 4.0%, Polyvinyl Alcohol 15.0%, Hyaluronic Acid Extract 5.0%, Beta Glucan 7.0%, Allantoin 0.1%, Honey Extract 0.5%, Nonyl Phenyl Ether 0.4%, Polysorbate 60 1.2%, Ethanol 6.0%, Purified Water
  • Ointments were prepared in a conventional manner according to the compositions described below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une nouvelle utilisation d'un extrait de rhizome de Nardostachys, et plus particulièrement, une composition pour le traitement du cancer du pancréas et une composition pour des produits cosmétiques contenant, comme ingrédient actif, un extrait de rhizome de Nardostachys ayant d'excellents effets prophylactiques et thérapeutiques sur le cancer du pancréas. L'extrait de rhizome de Nardostachys, selon la présente invention, élimine la prolifération des cellules cancéreuses du pancréas et induit leur apoptose, et peut ainsi être utilisé efficacement dans la prophylaxie et le traitement du cancer du pancréas.
PCT/KR2012/002467 2011-03-31 2012-04-02 Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys Ceased WO2012134251A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110029418A KR20120111109A (ko) 2011-03-31 2011-03-31 감송향 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR10-2011-0029418 2011-03-31

Publications (2)

Publication Number Publication Date
WO2012134251A2 true WO2012134251A2 (fr) 2012-10-04
WO2012134251A3 WO2012134251A3 (fr) 2013-03-07

Family

ID=46932192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002467 Ceased WO2012134251A2 (fr) 2011-03-31 2012-04-02 Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys

Country Status (2)

Country Link
KR (1) KR20120111109A (fr)
WO (1) WO2012134251A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014112663A1 (fr) * 2013-01-17 2014-07-24 주식회사 한국전통의학연구소 Composition pharmaceutique pour prévenir et traiter la pancréatite chronique comprenant un extrait de nardostachys jatamansi en tant que substance active

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100546735B1 (ko) * 1998-09-23 2006-04-20 주식회사 엘지생활건강 피부미백제 조성물
JP2001192338A (ja) * 2000-01-11 2001-07-17 Pola Chem Ind Inc ストレスの悪影響からの回復促進剤及びそれを含有してなる皮膚外用剤
WO2004112692A2 (fr) * 2003-05-19 2004-12-29 Amazon Biotech Inc. Compositions therapeutiques a base de plantes medicinales
US7378112B2 (en) * 2005-11-28 2008-05-27 Sahajanand Biotech Pvt. Ltd. Herbal composition to improve psychological functions as an anxiolytic, tranquilizer, and non-narcotic sedative, as well as other physiological functions
KR101023780B1 (ko) * 2009-02-23 2011-03-21 주식회사한국전통의학연구소 감송향 추출물을 활성성분으로 포함하는 급성 췌장염의 예방 및 치료용 약학적 조성물

Also Published As

Publication number Publication date
KR20120111109A (ko) 2012-10-10
WO2012134251A3 (fr) 2013-03-07

Similar Documents

Publication Publication Date Title
KR20120092283A (ko) 합환피 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
WO2012134250A2 (fr) Composition pour le traitement du cancer du rein et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
WO2012134251A2 (fr) Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20130025336A (ko) 천초근 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR20130022737A (ko) 포도근 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR20120122425A (ko) 독활 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
WO2014069695A1 (fr) Composition pour traiter le cancer du pancréas et aliment santé fonctionnel contenant un extrait de boswellia
KR20120092274A (ko) 애엽 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
KR101794145B1 (ko) 안식향 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR101752486B1 (ko) 백축 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR20120122405A (ko) 백축 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
KR20120092280A (ko) 천초근 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
KR20130022733A (ko) 천황련 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR20120122446A (ko) 육두구 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR20120122438A (ko) 소자 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
WO2012134168A2 (fr) Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait d'herbe de lysimachia foenum-graecum
KR20130023177A (ko) 호초 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR20130022393A (ko) 토목향 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
WO2014069693A1 (fr) Composition pour traiter le cancer du pancréas et composition cosmétique contenant un extrait de semence de pharbitidis
KR101794142B1 (ko) 무이 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
WO2012134163A2 (fr) Composition pour le traitement du cancer du poumon et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
WO2014077436A1 (fr) Composition contenant de l'extrait de radix inulae utilisable pour traiter le cancer du pancréas et à des fins cosmétiques
WO2013147340A1 (fr) Composition et complément alimentaire pour traiter le cancer du poumon, contenant un extrait d'encens
KR20120122409A (ko) 소자 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2014077432A1 (fr) Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12765964

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12765964

Country of ref document: EP

Kind code of ref document: A2